Tag Archives: Do Kim

VBI Vaccines (VBIV) Gets a Buy Rating from BMO Capital

In a report issued on June 25, Do Kim from BMO Capital maintained a Buy rating on VBI Vaccines (VBIV – Research Report), with a price target of $4.00. The company’s shares closed last Monday at $3.10. According to TipRanks.com,

BMO Capital Maintains a Buy Rating on Scholar Rock Holding (SRRK)

In a report issued on June 24, Do Kim from BMO Capital maintained a Buy rating on Scholar Rock Holding (SRRK – Research Report), with a price target of $33.00. The company’s shares closed last Monday at $18.25. According to

BMO Capital Reaffirms Their Buy Rating on Retrophin (RTRX)

BMO Capital analyst Do Kim maintained a Buy rating on Retrophin (RTRX – Research Report) today and set a price target of $34.00. The company’s shares closed last Tuesday at $16.95. According to TipRanks.com, Kim is a 5-star analyst with

Analysts Are Bullish on Top Healthcare Stocks: Alnylam Pharma (ALNY), Vanda (VNDA)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Alnylam Pharma (NASDAQ:ALNY), Vanda (NASDAQ:VNDA) and Johnson & Johnson (NYSE:JNJ) with bullish sentiments. Alnylam Pharma (ALNY) In a report issued on October

BMO Capital Reaffirms Their Buy Rating on Constellation Pharmaceuticals Inc (CNST)

In a report released today, Do Kim from BMO Capital maintained a Buy rating on Constellation Pharmaceuticals Inc (NASDAQ: CNST), with a price target of $19. The company’s shares opened today at $10.45. According to TipRanks.com, Kim is a 4-star

Replimune Group Inc (REPL) Received its Third Buy in a Row

After J.P. Morgan and Leerink Partners gave Replimune Group Inc (NASDAQ: REPL) a Buy rating last month, the company received another Buy, this time from BMO Capital. Analyst Do Kim maintained a Buy rating on Replimune Group Inc today and